Could HIF-1α be a novel biomarker for the clinical course and treatment of pulmonary embolism?
Bugra KergetDursun Erol AfşinAlperen AksakalSeda AşkınÖmer ArazPublished in: Turkish journal of medical sciences (2020)
HIF-1α can be used in the PE clinical risk stratification and monitoring of PE and may also serve as a valuable early indicator in intermediate high-risk PE, for which early reperfusion therapy is important.